Dong; Haidong
Patent Applications and Registrations
Patent applications and USPTO patent grants for Dong; Haidong.The latest application filed is for "rescuing cancer patients from resistance to treatment with inhibitors of pd-1/pd-l1 interactions".
- Dong; Haidong - Rochester MN
| Patent | Date |
|---|---|
| Rescuing Cancer Patients From Resistance To Treatment With Inhibitors Of Pd-1/pd-l1 Interactions App 20210361767 - Dong; Haidong ; et al. | 2021-11-25 |
| Methods for treating cancer in patients with elevated levels of Bim Grant 11,136,393 - Dong , et al. October 5, 2 | 2021-10-05 |
| Improving Anti-pd-1 Cancer Therapy App 20210003556 - Dong; Haidong | 2021-01-07 |
| Antibodies to B7-H1 Grant 10,875,923 - Dong December 29, 2 | 2020-12-29 |
| Modulation of Extracellular Vesicles with Electrical Stimulation App 20200384266 - Wang; Hai-Long ; et al. | 2020-12-10 |
| Methods And Materials For Treating Cancer App 20200338112 - Lou; Zhenkun ; et al. | 2020-10-29 |
| Soluble B7-H1 App 20200326344 - Kwon; Eugene D. ; et al. | 2020-10-15 |
| Antibodies To B7-h1 App 20200190196 - Dong; Haidong | 2020-06-18 |
| Targeting Dna-pkcs And B7-h1 To Treat Cancer App 20200061077 - Dong; Haidong | 2020-02-27 |
| Targeting DNA-PKcs and B7-H1 to treat cancer Grant 10,517,875 - Dong Dec | 2019-12-31 |
| Distinguishing Antagonistic And Agonistic Anti B7-h1 Antibodies App 20190361033 - Dong; Haidong | 2019-11-28 |
| Methods For Treating Cancer In Patients With Elevated Levels Of Bim App 20190315869 - Dong; Haidong ; et al. | 2019-10-17 |
| Distinguishing antagonistic and agonistic anti B7-H1 antibodies Grant 10,302,653 - Dong | 2019-05-28 |
| Methods for treating cancer in patients with elevated levels of BIM Grant 10,259,875 - Dong , et al. | 2019-04-16 |
| Methods and materials for treating cancer Grant 10,167,336 - Dong , et al. J | 2019-01-01 |
| Soluble B7-H1 App 20170363634 - Kwon; Eugene D. ; et al. | 2017-12-21 |
| Targeting Dna-pkcs And B7-h1 To Treat Cancer App 20170173030 - Dong; Haidong | 2017-06-22 |
| Distinguishing Antagonistic And Agonistic Anti B7-h1 Antibodies App 20170089918 - Dong; Haidong | 2017-03-30 |
| Methods For Treating Cancer In Patients With Elevated Levels Of Bim App 20160251437 - Dong; Haidong ; et al. | 2016-09-01 |
| Methods And Materials For Treating Cancer App 20160176967 - Dong; Haidong ; et al. | 2016-06-23 |
| B7-h1 And B7-h4 In Cancer App 20160153996 - Kwon; Eugene D. ; et al. | 2016-06-02 |
| B7-h1 And Survivin In Cancer App 20160154000 - Kwon; Eugene D. ; et al. | 2016-06-02 |
| Methods and materials for treating cancer Grant 9,302,005 - Dong , et al. April 5, 2 | 2016-04-05 |
| Soluble B7-H1 App 20150111232 - Kwon; Eugene D. ; et al. | 2015-04-23 |
| B7-h1 And B7-h4 In Cancer App 20140335541 - Kwon; Eugene D. ; et al. | 2014-11-13 |
| B7-h1 And Survivin In Cancer App 20140329248 - Kwon; Eugene D. ; et al. | 2014-11-06 |
| Methods And Materials For Treating Cancer App 20140271674 - Dong; Haidong ; et al. | 2014-09-18 |
| B7-h1 And Survivin In Cancer App 20100015642 - Kwon; Eugene D. ; et al. | 2010-01-21 |
| B7-h1 And B7-h4 In Cancer App 20090215084 - Kwon; Eugene D. ; et al. | 2009-08-27 |
| Soluble B7-H1 App 20090176317 - Kwon; Eugene D. ; et al. | 2009-07-09 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 